October 1, 2009
Presentation of Phase 2 Data on ATX-101, a First-in-Class, Novel, Injectable Drug For The Reduction of Localized Fat
11:00 a.m. (MST/PDT) Friday, Oct. 2, 2009 (2:00 p.m. Eastern, 1:00 p.m. Central)
The American Society for Dermatologic Surgery (ASDS) and American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS)
Joint Annual Meeting, Phoenix, AZ
Scientific Session (CS263) - “You Asked for It”
In a rapidly growing market of minimally-invasive, non- surgical facial rejuvenation, the reduction of facial fat deposits to restore and reshape the jawline remains one of the largest unmet patient needs. Currently there are no FDA approved drugs to reduce excess localized fat.
KYTHERA is developing ATX-101 to address this need. ATX- 101 is a first-in-class injectable drug for the reduction of localized fat. The initial application of ATX-101 is for the reduction of submental (under the chin) fat.
KYTHERA CEO Keith Leonard is available to discuss the Phase 2 data beginning at 12 p.m. Friday.
ATX-101 is a first-in-class injectable drug being studied for the reduction of small volumes of fat. It is based on an endogenous compound with unique features including selectivity for adipocytes and rapid clearance. ATX-101 clinical research is focused on reduction of localized fat deposits, including submental fat. KYTHERA has completed two randomized, double-blind, placebo-controlled, Phase 2 studies with ATX-101 in the reduction of submental fat and two Phase 1 pharmacokinetic and histology studies.